Do targeted therapies promote angiogenesis?
Answers from top 10 papers
More filters
| Papers (10) | Insight |
|---|---|
01 Jun 2014 | These studies show that precocious angiogenesis is inhibitory for regeneration, and provide compelling evidence that the regulation of angiogenesis is a critical factor in designing therapies aimed at stimulating mammalian regeneration. |
30 Citations | These novel interactions are critical for pathophysiological angiogenesis, suggesting that these sites could be selectively targeted by therapeutics to modulate angiogenesis. |
31 Citations | These local therapies may allow broader use of therapeutic angiogenesis while avoiding and treating potentially undesirable effects. |
| This mechanism may be targeted to control angiogenesis-dependent diseases. | |
| Results and conclusions Several evidences have demonstrated a role for biotechnological therapies in angiogenesis inhibition. | |
53 Citations | Innovative drug delivery systems can increase the effectiveness of therapies used to treat angiogenesis-related diseases. |
| Therefore, angiogenesis inhibitors may be useful adjuncts to conventional therapies in the treatment of these diseases. | |
26 Citations | We predict that effective antiangiogenic therapies will block a tumor's ability to augment angiogenesis initiation rather than subsequent neovessel growth. |
40 Citations | These new aspects, that critically regulate angiogenesis and vascular homeostasis in health and diseased, represent unforeseen new ground to develop anti-angiogenic therapies. |
| These studies reveal striking differences between physiological and pathological angiogenesis potentially important for the development of tumor-specific, vascular-targeted therapies. |
Related Questions
What is targeted treatment of HER-2?5 answersTargeted treatment of HER-2 involves the use of specific therapies that specifically target the HER-2 receptor in breast cancer cells. These therapies aim to inhibit the overactive signaling pathways associated with HER-2 overexpression, which contribute to tumor growth and progression. Currently approved targeted therapies for HER-2 positive breast cancer include monoclonal antibodies such as trastuzumab, pertuzumab, and margetuximab, as well as antibody-drug conjugates like trastuzumab-emtansine (T-DM1) and trastuzumab-deruxtecan (T-DXd). In addition, tyrosine kinase inhibitors like lapatinib and tucatinib have also shown efficacy in HER-2 positive breast cancer. These targeted therapies can be used alone or in combination with other drugs, immune checkpoint inhibitors, CAR-T cells, CAR-NK, CAR-M, and vaccines to overcome resistance and improve treatment outcomes. Nanoparticle-based approaches have also been explored as a promising strategy for HER-2 positive breast cancer therapy and diagnosis. Furthermore, the development of dual-targeted therapies that simultaneously block HER-2 and integrin receptors has shown promising results in overcoming tumor resistance.
What are targeting ligands for targeted cancer therapy?5 answersTargeting ligands for targeted cancer therapy include AB toxins, phytoestrogens, small molecules, and aptamers. AB toxins are highly poisonous molecules that have a nanomolar affinity for their target cell receptors, making them promising tools for developing new methods for targeting anticancer therapies. Phytoestrogens, specifically tanshinone IIA, have shown good biosafety characteristics and affinity for estrogen receptors, making them suitable ligands for nanodelivery systems in breast tumors. Small molecules, including chemotherapeutics, have a higher affinity for cancer receptors and can assist in drug cellular uptake through endocytosis. Aptamers, such as those targeting tumor markers and glycoproteins, have high target affinity and specificity, making them attractive ligands for targeted drug delivery in cancer therapy.
What is targeted therapy?5 answersTargeted therapy refers to a group of drugs that selectively target tumor-specific cellular processes, aiming to destroy cancer cells with higher specificity than traditional agents. These therapies include monoclonal antibodies and small molecule inhibitors, which have significantly changed the treatment of cancer over the past decade. They are designed to inhibit the products of oncogenes involved in neoplastic transformation, either directly or at a later stage. Targeted therapies are more tumor-specific and less toxic than traditional chemotherapy, leading to better clinical outcomes for cancer patients. However, there are challenges associated with targeted therapies, such as molecular identification, drug resistance, and the need for reliable biomarkers. Despite these challenges, targeted therapy has shown excellent efficacy in pre-clinical and clinical trials, making it a promising approach for personalized and precision treatment of various diseases, including cancer and cardiovascular diseases.
Why anti-cancer targeted monotherapies fail?5 answersAnti-cancer targeted monotherapies fail due to several reasons. One of the main reasons is the development of resistance by cancer cells against targeted therapies. Cancer cells can develop mechanisms to overcome the effects of targeted drugs, leading to treatment failure. Another reason is the limited effectiveness of monotherapy in inhibiting cancer growth and survival pathways. Targeted inhibitors may initially show potency and selectivity, but the development of resistance and limited improvement in patient outcomes are common challenges. Additionally, the high cost and inadequate bioavailability of molecularly tailored drugs contribute to their failure. These drugs may have adverse side effects and may not effectively reach the target cells. Therefore, the combination of targeted inhibitors with common metabolic regulators is being explored to overcome resistance and improve treatment outcomes.
What percentage of breast cancer treatments are targeted therapeutics?5 answersApproximately 20% of breast cancers are associated with amplification or overexpression of human epidermal growth factor receptor 2 (HER2), and targeted therapeutics are the cornerstone of cancer therapeutic strategies for these cases. For metastatic breast cancer (mBC), recent advances in molecularly targeted agents have enhanced the repertoire of treatment options, including immunotherapies. Triple-negative breast cancer (TNBC), which accounts for 10-20% of breast cancer cases, often responds well to chemotherapy, but new targeted therapies are being investigated. Currently, no FDA-approved targeted therapies are available for TNBC. Overall, the use of targeted therapeutics varies depending on the subtype of breast cancer, with HER2-positive breast cancer having a higher percentage of targeted treatments compared to TNBC.
Can tumors manipulate angiogenesis?9 answers